<!DOCTYPE html>
<html>
<head>
	<meta charset="utf-8">
	<title>ABX Spectrum</title>

	<link rel="icon" 
      type="image/png" 
      href="Images/ABXfav.png">

	<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/normalize/7.0.0/normalize.css">

	<link rel="stylesheet" href="Styles/featherlight.css">

	<link rel="stylesheet" href="Styles/main.css">

	<script src="Scripts/jquery.js"></script>

<!-- 	<script src="Scripts/app.js"></script> -->

	<script src="Scripts/featherlight.min.js"></script>

	<meta name="viewport" content="width=device-width, initial-scale=1">


</head>
<body>

<div id="wrapper">

<header class="one-edge-shadow">
	<section class="col-one">

	<a href="#" data-featherlight="#top1">
		<img class="sizing" src="Images/v1_top1_gp.png">

	</a>
	<div id="lightbox-hide">
	<div id="top1">
		<p><b>GRAM POSITIVES</b>
		<br>
		<br>Cocci:
		<br>Enterococcus, Staphylococcus, and Streptococcus.
		<br>VR = Vancomycin Resistant Enterococcus
		<br>MR = Methicillin-Resistant Staph. Aureus</p>
	</div>


	</section>

	<section class="col-two">
	<a href="#" data-featherlight="#top2">
		<img class="sizing" src="Images/v1_top2_gn.png">
	</a>
	<div id="lightbox-hide">
	<div id="top2">
		<p><b>GRAM NEGATIVES</b>
		<br>
		<br>Bacilli:
		<br>Community Infections
		<br>GI = E. Coli, Klebsiella, and Proteus
		<br>Resp = Haemophilus influenzae, and Moraxella
		<br>Nosocomial Infections
		<br>SPACE = Serratia, Providencia, Acinetobacter, Citrobacter, Enterobacter, and Morganella.
		<br>Pseud. = Pseudomonas
		</p>

	</div>
	</section>

	<section class="col-three">
	<a href="#" data-featherlight="#top3">
		<img class="sizing" src="Images/v1_top3_an.png">
	</a>
	<div id="lightbox-hide">
	<div id="top3">
		<p><b>ANAEROBES</b>
		<br>
		<br>Clostridium (GP bacilli)
		<br>Bacteroides (GN bacilli) - metro., zosyn, mero. only
		</p>

	</div>

	</section>

	<section class="col-four">

		<a href="#" data-featherlight="#top4">
		<img class="sizing" src="Images/v1_top4_at.png">
	</a>
	<div id="lightbox-hide">
	<div id="top4">
		<p>
		<b>ATYPICALS</b>
		<br>
		<br>Legionella - older patients
		<br>Chlamydia - younger patients
		<br>Mycoplasma - younger patients
		</p>

	</div>
		
	</section>

</header>

<main>
	
	<section class="row-one">
	<a href="#" data-featherlight="#fl1">
		<img class="sizing" src="Images/v1_bot01_pcn.png">

	</a>
	<div id="lightbox-hide">
	<div id="fl1">
		<p>
		<b>PENICILLINS</b>
		<br>
		<br>Penicillin G (IV, IM)
		<br>Penicillin VK (PO)
		</p>
	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl2">
		<img class="sizing" src="Images/v1_bot02_am.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl2">
		<p>
			<b>AMINOPENICILLINS</b>
			<br>
			<br>Ampicillin (IV)
			<br>Amoxicillin (PO)
			<br><i>
			<br>No Klebsiella activity</i>
		</p>

	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl3">
		<img class="sizing" src="Images/v1_bot03_asp.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl3">
	<p>
		<b>ANTISTAPH PENICILLINS</b>
		<br>
		<br>Oxacillin (IV)
		<br>Nafcillin (IV)
		<br>Dicloxacillin (PO)
		<br><i>
		<br>HEPATIC ELIMINATION
		<br>Coag(-) staph. is generally resistant (>80%)</i>
	</p>

	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl4">
		<img class="sizing" src="Images/v1_bot04_una.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl4">
	<p>
	<b>AUGMENTIN/UNASYN</b>
	<br>
	<br>Augmentin (Amoxicillin/Clavulanate) (PO)
	<br>Unasyn (Ampicillin/Sulbactam) (PO)
	<br><i>
	<br>Unasyn only covers acinetobacter (SPACE)
	<br>Rising e. coli resistance
	<br>Only treats H/N anaerobes</i></p></div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl5">
		<img class="sizing" src="Images/v1_bot05_zosy.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl5">
	<p>
		<b>ZOSYN</b>
		<br>
		<br>Zosyn (Piperacillin/Tazobactam) (IV)
		<br><i>
		<br>Poor activity versus coag(-) staph.
		<br>Can treat lower anaerobes</i>
	</p></div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl6">
		<img class="sizing" src="Images/v1_bot06_1gc.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl6">
	<p>
		<b>1G CEPHALOSPORINS</b>
		<br>
		<br>Cefazolin (IV) "Ancef"
		<br>Cephalexin (PO)
		<br><i>
		<br>Cefazolin can be used in penicillin allergy
		<br>Cefazolin has some G(+) coverage for prophylaxis</i>
	</p>
	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl7">
		<img class="sizing" src="Images/v1_bot07_2gc.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl7">
	<p>
		<b>2G CEPHALOSPORINS</b>
		<br>
		<br>Cefuroxime (PO,IV)
		<br>Cefotetan (IV)
		<br>Cefoxitin (IV)
		<br><i>
		<br>Cefuroxime gains h. flu, enterobacter, neisseria
		<br>Cefotetan and Cefoxitin are cephamycins
		<br>Cefotetan and Cefoxitin lack G(+) coverage</i>

	</p>
	</div>		
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl8">
		<img class="sizing" src="Images/v1_bot08_3gc.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl8">
	<p>
		<b>3G CEPHALOSPORINS</b>
		<br>
		<br>Ceftriaxone (IV) "Rocephin"
		<br>Cefotaxime (IV)
		<br>Cefpodoxime (PO)
		<br>Cefdinir (PO)
		<br>Cefixime (PO)
		<br>Ceftazidime (IV) *Antipseudomonal activity
		<br>
		<br><i>NO RENAL ADJUSTMENT (Ceftriaxone only)
		<br>Ceftazidime lacks G(+) cover
		<br>Ceftriaxone penetrates CSF
		<br>Avoid Ceftriaxone if low AmpC lactamase levels</i>
	</p>
	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl9">
		<img class="sizing" src="Images/v1_bot09_4gc.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl9">
		<p>
		<b>4G CEPHALOSPORINS</b>
		<br>
		<br>Cefepime (IV)
		<br>
		<br><i>Avoid use with mid/high AmpC levels
		<br>Low cross-react with penicillin allergy
			</i>
	</p>
	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl10">
		<img class="sizing" src="Images/v1_bot10_5gc.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl10">
	<p>
		<b>5G CEPHALOSPORINS</b>
		<br>
		<br>Ceftaroline (IV)
		<br>
		<br><i>Often reserved for refractory MRSA or VRSA</i>
	</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl11">
		<img class="sizing" src="Images/v1_bot11_avz.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl11">		
		<p>
			<b>ZERBAXA/AVYCAZ</b>
			<br>
			<br>Zerbaxa (Ceftolozane/Tazobactam) (IV)
			<br>Avycaz (Ceftazidime/Avibactam) (IV)
			<br>
			<br><i>Limited FDA-approved indications
			<br>Avycaz can be used for ESBL and CRE (KPC only)
			<br>Zerbaxa can be used for ESBL</i>
		</p></div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl12">
		<img class="sizing" src="Images/v1_bot12_cbp.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl12">
	<p>
		<b>CARBAPENEMS</b>
		<br>
		<br>Meropenem (IV)
		<br>Imipenem/Cilastatin (IV)
		<br>Ertapenem (IV)
		<br>Doripenem (IV)
		<br>
		<br><i>Often reserved for ESBL (DOC)
		<br>Can treat lower anaerobes
		<br>May cause seizures (Imipenem/Cilastatin more than others)
		<br>Ertapenem lacks acinetobacter coverage
		<br>Cilastatin px imipenem breakdown</i>
	</p>
	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl8">
		<img class="sizing" src="Images/v1_bot13_mon.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl13">
	<p>
		<b>MONOBACTAM</b>
		<br>
		<br>Aztreonam (IV)
		<br>
		<br><i>Often reserved for PCN-allergic patients</i>
	</p>
	</div>
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl14">
		<img class="sizing" src="Images/v1_bot14_amg.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl14">
	<p>
		<b>AMINOGLYCOSIDES</b>
		<br>
		<br>Amikacin (IV,IM)
		<br>Gentamicin (IV,IM)
		<br>Tobramycin (IV,IM)
		<br>
		<br><i>Causes nephrotoxicity
		<br>Can use low dose w/ beta-lactam for G(+) synergy</i>
	</p></div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl15">
		<img class="sizing" src="Images/v1_bot15_flq.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl15">
		<p>
			<b>FLUOROQUINOLONES</b>
			<br>
			<br>Levofloxacin (IV,PO)
			<br>Ciprofloxacin (IV,PO)
			<br>Moxifloxacin (IV,PO)
			<br>
			<br><i>May cause QT-prolongation (M>C>L)
			<br>Moxi. does not concentrate in the urine well
			<br>Moxi only treats H/N anaerobes
			<br>Separate dosing from polyvalent cations
			</i>
		</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl16">
		<img class="sizing" src="Images/v1_bot16_mcr.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl16">
	<p>
		<b>MACROLIDES</b>
		<br>
		<br>Azithromycin (PO,IV)
		<br>Clarithormycin (PO)
		<br>
		<br>BACTERIOSTATIC
		<br><i>Causes QT prolongation
		<br>Distributes rapidly/well to tissue, but not blood
		</i>
	</p></div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl17">
		<img class="sizing" src="Images/v1_bot17_ttc.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl17">
	<p>
		<b>TETRACYCLINES</b>
		<br>
		<br>Doxycycline (IV,PO)
		<br>Minocycline (IV,PO)
		<br>
		<br>BACTERIOSTATIC
		<br><i>Take with water to px esophagitis
		<br>Separate dosing from polyvalent cations
		</i>
	</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl18">
		<img class="sizing" src="Images/v1_bot18_van.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl18">
		<p>
			<b>VANCOMYCIN</b>
			<br>
			<br>Vancomycin (IV,PO)
			<br>Dalbavancin, Oritavancin, Televancin (IV)
			<br>
			<br>High Trough Goal: Endocarditis, OM/PJI, ICU HCAP/sepsis and MRSA (MIC=1)
			<br>Very High Trough Goal: Meningitis/CNS Infections
			<br><i>Causes nephrotoxicity (Potential increased incidence with long term coadmin with PTZ)
			<br>PO formulation for c. diff only (DOC)
			<br>Prevent Red Man Synd. by slowing infusion (by 50%)
			<br>Vancins cover G(+) anaerobes
			<br>Oritavancin covers VRE
			</i>
		</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl19">
		<img class="sizing" src="Images/v1_bot19_oxa.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl19">
	<p>
		<b>OXAZOLIDINONES</b>
		<br>
		<br>Linezolid (IV,PO)
		<br>Tedizolid (IV,PO) -reserved for resistance
		<br>
		<br>BACTERIOSTATIC (except strep. sp)
		<br><i>Causes myelosuppression with prolonged use (>2w)
		<br>May cause serotonin syndrome</i>
	</p></div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl20">
		<img class="sizing" src="Images/v1_bot20_dap.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl20">
	<p>
		<b>DAPTOMYCIN</b>
		<br>
		<br>Daptomycin (IV)
		<br>
		<br><i>No activity in the lung (inactivated)</i>
	</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl21">
		<img class="sizing" src="Images/v1_bot21_clin.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl21">
	<p>
		<b>CLINDAMYCIN</b>
		<br>
		<br>Clindamycin (IV,PO)
		<br>
		<br>BACTERIOSTATIC
		<br>CA: Covers community acquired-MRSA
		<br><i>Only treats H/N anaerobes</i>
	</p></div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl22">
		<img class="sizing" src="Images/v1_bot22_tig.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl22">
	<p>
		<b>TIBECYCLINE</b>
		<br>
		<br>Tigecycline (IV)
		<br>
		<br>HEPATIC METABOLISM
		<br>BACTERIOSTATIC (Except strep. pneumo and listeria)
		<br><i>Used primarily for G(-) coverage
		<br>Lacks Proteus, Providencia, and Pseudomonas coverage
		<br>Can treat Acinetobacter if MIC less than 4
		<br>Potentially effective for nosocomial MRSA
		<br>Does not concentrate well in blood or urine
		<br>Concentrates well in lung and abdomen
		<br>Covers ESBL and CRE if desperate</i>
		<br><b>BBW: Increase in all-cause mortality</b>
	</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl23">
		<img class="sizing" src="Images/v1_bot23_mtr.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl23">
	<p>
		<b>METRONIDAZOLE</b>
		<br>
		<br>Metronidazole (IV, PO)
		<br>
		<br><i>Can treat lower anaerobes</i>
	</p>
	</div>	
	</section>

	<section class="row">
	<a href="#" data-featherlight="#fl24">
		<img class="sizing" src="Images/v1_bot24_bac.png">
	</a>
	<div id="lightbox-hide">
	<div id="fl24">
	<p>
		<b>BACTRIM</b>
		<br>
		<br>TMP/SMX (PO, IV)
		<br>
		<br>CA: Covers community acquired-MRSA
		<br><b>SULFA DRUG</b>
		<br><i>Dosed based on TMP component
		<br>Does not concentrate in the blood well
		<br>Causes hyperkalemia and pseudo-sCr elevation
		<br>DOC: Stenotrophomonas Maltophilia</i>
	</p>
	</div>	
	</section>


</main>

<footer>
	<p>&copy; 2017. TGIV</p>	
</footer>

</div>
</body>
</html>